Mesenchymal Stem Cell for Blood Cancers

Phase 1 & 2

Waitlist Available

Led By Amanda Olson

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at day 30 post msc infusion

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether it is feasible to use cord blood-derived mesenchymal stem cells (MSCs) to treat patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection. If it is successful, a larger trial will be conducted to compare the effect of MSCs with standard of care in these patients.

Eligible Conditions

Blood Cancers
COVID-19
COVID-19 Infection
Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at day 30 post msc infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at day 30 post msc infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and at day 30 post msc infusion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of composite serious adverse events (Phase I)

Secondary study objectives

Clinical parameters (Phase I)

Incidence of infusion-related adverse events (Phase I)

Laboratory markers (Phase I)

+7 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Pilot study (mesenchymal stem cells)Experimental Treatment1 Intervention

Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.

Group II: Phase II Arm I (mesenchymal stem cells)Experimental Treatment1 Intervention

Patients receive MSCs as in the Pilot study.

Group III: Phase II Arm II (standard of care)Active Control1 Intervention

Patients receive standard of care.

Do I qualify?Apply below to find out